At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 49 enrolled
Drug / intervention
Linagliptin +1 moredrug
Likely dose
Linagliptin 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes
In Brief
A Phase 4 clinical trial evaluating Linagliptin and Placebo for Type 2 Diabetes and Coronary Artery Disease. Completed, enrolled 49 participants across 1 site.
Detailed Summary
This study is planned to evaluate if linagliptin can improve endothelial function in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on arginine bioavailability ratios and postchallenge glycaemic control will be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Coronary Artery Disease
CountriesAustria
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJan 2015
Primary CompletionJan 2017
Study CompletionMar 2017
TodayJul 2026
First PostedJan 29, 2015
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.4 years ago
Interventions
Linagliptindrug
The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
Placebodrug
The subject will receive placebo orally once daily for 12 weeks.